
Opinion|Videos|February 13, 2025
Clinical Impact of Hypophosphatemia
Panelists discuss how the lower incidence of hypophosphatemia and related complications with ferric derisomaltose and ferric isomaltoside compared with ferric carboxymaltose influences treatment selection, monitoring protocols, and preventive strategies for patients requiring intravenous iron therapy.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- Considering the incidence of hypophosphatemia in patients with IDA was significantly lower with the use of FDI and FXT than with FCM therapy, how does this impact the choice of treatment?
- How do you monitor phosphate levels?
- A retrospective analysis found a significantly higher combined event rate of fracture, radiological signs of osteomalacia, and kidney stones among patients treated with FCM than after ferric derisomaltose (FDI) treatment. Do these results impact your clinical decision-making?
- What potential interventions or preventative measures could be taken to mitigate the risk of hypophosphatemia in patients receiving IV iron formulations?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Expiring ACA Subsidies and CMS Payment Models Raise Costs for Consumers and Employers
2
RSV Vaccination Effective in Older Adults, but Protection Declines Over Time
3
Older Adults Drive Hospitalizations, Costs in the US 2024-2025 Influenza Season
4
Discontinuing GLP-1s Before or Early in Pregnancy Tied to Weight Gain, Pregnancy Complications
5















































